Testing a new treatment for immune-related kidney disease
Treatments studied
Part of Kidney & urinary clinical trials.
This trial tests a new medicine called LP-005 for people with kidney disease caused by an overactive part of the immune system called the complement system. It aims to see if the drug is safe and effective for reducing kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 65 with a complement-mediated kidney disease.
- Weigh at least 40 kg (about 88 lbs) with a BMI between 15 and 35.
- Must avoid pregnancy or fathering a child during the trial and for 3 months after.
- No serious infections in the past 4 weeks, and no history of meningococcal infection.
- Cannot have used certain other investigational drugs or complement inhibitors recently.
- No active cancer in the last 5 years, except for some fully removed skin or early-stage cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SIM0278 for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if the drug can help control the disease and improve kidney health.
This trial tests a new medicine called STR-P004 for people with kidney diseases caused by the immune system attacking the kidneys. The study checks if the medicine is safe and if the body can tolerate it, which may help reduce kidney damage.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This trial tests an experimental drug called ADX-038 for people with certain types of kidney disease that are driven by the complement system (a part of the immune system). The study aims to see if ADX-038 can help slow down or improve kidney function.
This trial tests a new treatment for people with lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and protect kidney function.
This trial tests a new medication called MSC303, given as a shot under the skin, for people with two kinds of immune-related kidney diseases. The goal is to see if it can help control the disease and improve kidney function.
Hear when a new Complement-mediated Renal Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.